MétaCan
Menu
← Back to cohort
Record W2347028544 · doi:10.1371/journal.pone.0154206

Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

2016· review· en· W2347028544 on OpenAlexafffund
Zhixia Li, Yuan Zhang, Xiaochi Quan, Zhirong Yang, Xian‐Tao Zeng, Linong Ji, Feng Sun, Siyan Zhan

Bibliographic record

VenuePLoS ONE · 2016
Typereview
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsMcMaster University
FundersSpecialized Research Fund for the Doctoral Program of Higher Education of ChinaZhongnan Hospital of Wuhan UniversityPeking UniversityNational Natural Science Foundation of ChinaMcMaster University
KeywordsDulaglutideLiraglutideMedicineExenatideSitagliptinPlaceboHypoglycemiaInternal medicineType 2 diabetesCochrane LibraryLixisenatideGlycemicDiscontinuationInsulin glargineRandomized controlled trialPharmacologyEndocrinologyDiabetes mellitusInsulin

Abstract

fetched live from OpenAlex

OBJECTIVE: To synthesize current evidence of the impact of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on hypoglycemia, treatment discontinuation and glycemic level in patients with type 2 diabetes. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Literature search (Medline, Embase, the Cochrane library), website of clinical trial, bibliographies of published systematic reviews. ELIGIBILITY CRITERIA: Randomized controlled trials with available data comparing GLP-1 RAs with placebo or traditional anti-diabetic drugs in patients with type 2 diabetes. DATA SYNTHESIS: Traditional pairwise meta-analyses within DerSimonian-Laird random effects model and network meta-analysis within a Bayesian framework were performed to calculate odds ratios for the incidence of hypoglycemia, treatment discontinuation, HbA1c<7.0% and HbA1c<6.5%. Ranking probabilities for all treatments were estimated to obtain a treatment hierarchy using the surface under the cumulative ranking curve (SUCRA) and mean ranks. RESULTS: 78 trials with 13 treatments were included. Overall, all GLP-1 RAs except for albiglutide increased the risk of hypoglycemia when compared to placebo. Reduction in the incidence of hypoglycemia was found for all GLP-1 RAs versus insulin (except for dulaglutide) and sulphonylureas. For the incidence of treatment discontinuation, increase was found for exenatide, liraglutide, lixisenatide and taspoglutide versus placebo, insulin and sitagliptin. For glycemic level, decrease was found for all GLP-1 RAs versus placebo. Dulaglutide, exenatide long-acting release (exe_lar), liraglutide and taspoglutide had significant lowering effect when compared with sitagliptin (HbA1c<7.0%) and insulin (HbA1c<6.5%). Finally, according to SUCRAs, placebo, thiazolidinediones and albiglutide had the best decrease effect on hypoglycemia; sulphanylureas, sitagliptin and insulin decrease the incidence of treatment discontinuation most; exe_lar and dulaglutide had the highest impact on glycemic level among 13 treatments. CONCLUSIONS: Among 13 treatments, GLP-1 RAs had a significant reduction with glycemic level but a slight increase effect on hypoglycemia and treatment discontinuation. While albiglutide had the best decrease effect on hypoglycemia and treatment discontinuation among all GLP-1 RAs. However, further evidence is necessary for more conclusive inferences on mechanisms underlying the rise in hypoglycemia.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.034
metaresearch head score (Gemma)0.076
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.034
Threshold uncertainty score0.181

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0340.076
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0180.048
Bibliometrics0.0090.008
Science and technology studies0.0010.001
Scholarly communication0.0040.002
Open science0.0020.002
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.085
GPT teacher head0.299
Teacher spread0.214 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations33
Published2016
Admission routes2
Has abstractyes

Explore more

Same venuePLoS ONE→Same topicDiabetes Treatment and Management→French-language works237,207→